Introduction
The HIMALAYA trial recently established a 5-year overall survival (OS) benchmark of 19.6% for durvalumab plus tremelimumab (Dur/Tre) in unresectable hepatocellular carcinoma (uHCC). However, the IMbrave150 trial was terminated early, and there are also very few reports of long-term real-world clinical data on atezolizumab plus bevacizumab (Atez/Bev). This study aimed to clarify the 5-year clinical outcomes and safety of first-line Atez/Bev in real-world practice.
Aims & Methods
We analyzed 307 patients with Child-Pugh class A and BCLC stage B/C who received Atez/Bev as their first-line systemic therapy between 2020 and 2021 across multiple centers. Treatment response was assessed based on objective response rate (ORR) and disease control rate (DCR), determined according to RECIST v1.1, while progression-free survival (PFS), overall survival (OS), and post-progression survival (PPS) were used to examine survival outcomes. Additionally, analyses of the incidence and severity of immune-related adverse events (irAEs) were performed.
Results
The cohort had a median age of 73 years, and 77.2% were male. BCLC-C was 57.7%. Median baseline ALBI score was -2.48. With a median observation period of 54.5 months (reverse Kaplan–Meier estimate), the ORR was 33.3% and the DCR was 80.3%. Median PFS was 7.1 months (95% CI: 5.9–8.4), and median OS was 22.3 months (95% CI: 19.7–26.5). Estimated 3-, 4-, and 5-year survival rates were 34.9%, 26.1%, and 19.0%, respectively. Post-progression treatment was administered to 74.6% of the patients, with a median PPS of 11.3 months. Hepatic function at the initiation of treatment was important; the median OS for patients with ALBI grade 1 reached 38.1 months. Regarding tumor burden, macrovascular invasion (MVI) was significantly associated with shorter survival (26.1 vs. 14.3 months, p<0.01). IrAEs were observed in 16.3% of the enrolled patients, and high-dose corticosteroids for irAEs were required in only 3.3% of patients.
Conclusion
First-line Atez/Bev achieved a 5-year survival rate of 19.0% in real-world clinical practice, approaching the long-term survival benchmark reported in the HIMALAYA trial (19.6%). In addition, Atez/Bev showed a favorable safety profile, with a low requirement for high-dose corticosteroids, suggesting a potentially lower incidence of severe immune-related adverse events compared with other immune-based combinations.